Author

L. Hoffer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:deep learning· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

S. Betzi· 3 shared X. Morelli· 3 shared C. Derviaux· 2 shared E. Pasquier· 2 shared K. Carrasco· 2 shared P. Roche· 2 shared Y. Collette· 2 shared A. Bolotokova· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

S. Betzi

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

CACHE Challenge #1: targeting the WDR domain of LRRK2, a Parkinson's Disease associated protein.

S. Ackloo, C. H. Arrowsmith, F. Ban, C. J. Barden, H. Beck, J. Beranek, F. Berenger, A. Bolotokova, G. Bret, M. Breznik, E. Carosati, I. Chau, Y. Chen, A. Cherkasov, D. Della Corte, , Klebe

The paper evaluates computational hit-finding methods for targeting the WDR domain of LRRK2, a Parkinson's disease protein, finding that diverse strategies yielded weakly potent compounds.

bioRxiv · Jul 18, 2024Biochemistry

CRCM5484: A BET- BDII Selective Compound With Differential Anti-Leukemic Drug Modulation

K. Carrasco, C. Montersino, C. Derviaux, M. Saez-Ayala, L. Hoffer, A. Restouin, R. Castellano, J. Casassa, P. Roche, E. Pasquier, S. Combes, X. Morelli, Y. Collette, S. Betzi

The paper identifies CRCM5484, a BDII-selective BET inhibitor, and shows its differential modulation of anti-leukemic drug activity in combination with other compounds.

bioRxiv · Dec 13, 2021Cancer Biology

Discovery of small molecule inhibitors of the PTK7/β-catenin interaction targeting the Wnt signaling pathway in colorectal cancer

L. Ganier, S. Betzi, C. Derviaux, P. Roche, C. Muller, L. Hoffer, X. Morelli, J.-P. Borg

This study identifies small molecule inhibitors of the PTK7/β-catenin interaction in colorectal cancer, showing anti-proliferative effects in cells with Wnt pathway mutations.

bioRxiv · Oct 15, 2021 · PreprintPharmacology & Toxicology

In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor

J. Ariey-Bonnet, K. Carrasco, M. Le Grand, L. Hoffer, S. Betzi, M. Feracci, P. Tsvetkov, F. Devred, Y. Collette, X. Morelli, P. Ballester, E. Pasquier

This paper identifies mebendazole as a potent MAPK14 inhibitor through in silico target prediction and experimental validation, revealing its potential for repurposing in brain tumor treatment.

bioRxiv · May 18, 2020Pharmacology & Toxicology